Skip to main content
. 2020 May 26;2020:9783859. doi: 10.1155/2020/9783859

Table 2.

Clinical, biochemical, and imaging parameters of normal BMI patients with T2DM and visceral adiposity before and after exenatide or humalog Mix25 intervention.

Variable Pre-exenatide Post-exenatide P value Pre-humalog Mix25 Post-humalog Mix25 P value
(n = 40) (n = 40) (n = 41) (n = 41)
BMI (kg/m2) 23.99 ± 1.2 22.68 ± 1.68 <0.01 23.89 (22.65-24.46) 23.12 (21.48-23.95) <0.01
Weight (kg) 68.08 ± 9.28 64.53 ± 10.41 <0.01 64 ± 6.39 62.24 ± 7.04 <0.01
WC (cm) 88.83 ± 5.58 84.21 ± 6.57 <0.01 88.39 ± 4.02 84.63 ± 4.76 <0.01
SBP (mmHg) 121.5 (117.5-136) 128 (117-135.5) 0.87 131.73 ± 14.45 128.7 ± 10.6 0.17
DBP (mmHg) 78 (75-84) 76 (70-81.5) 0.10 75.95 ± 9.5 72.2 ± 9.11 0.01
FPG (mmol/L) 9.14 ± 2.41 8.01 ± 2.03 0.01 9.45 ± 2.09 8.17 ± 1.76 <0.01
2hPBG (mmol/L) 15.95 ± 4.28 14.38 ± 3.37 0.039 17.27 ± 4.12 16.91 ± 3.34 0.47
FINS (mIU/L) 9.39 ± 3.13 9.18 ± 2.20 0.56 9.05 ± 2.42 10.28 ± 3.33 0.49
HbA1c (%) 8.43 ± 1.06 7.05 ± 1.04 <0.01 8.41 ± 0.91 7.42 ± 0.83 <0.01
TC (mmol/L) 5.21 ± 1.22 5.03 ± 0.86 0.26 5.01 ± 0.92 4.97 ± 0.79 0.82
TG (mmol/L) 1.35 (0.84-2.12) 1.26 (0.81-1.69) 0.13 1.46 (0.79-2.01) 1.09 (0.77-1.6) 0.01
AST (IU/L) 21 (18-25) 22 (18-27) 0.28 22.61 ± 5.94 22.73 ± 5.39 0.88
ALT (IU/L) 20 (16.5-34.5) 22 (16-30.5) 0.43 22 (18-26) 19 (17-24) 0.13
Creatinine (μmol/L) 57.43 ± 13.63 58.3 ± 13.12 0.52 53 (44-63) 60 (49-66) <0.01
FGF-21 (pg/mL) 359.64 ± 273.52 209.42 ± 164.22 <0.01 262.46 ± 208.96 226.35 ± 147.13 0.21
SAT (cm2) 129.85 ± 43.73 114.18 ± 44.39 <0.01 127.22 ± 48.29 125.7 ± 47.18 0.69
VAT (cm2) 80.56 ± 34.26 66.82 ± 30.07 <0.01 76.36 (60.26-96.91) 71 (50.24-88.14) <0.01
LFC (%) 22.96 ± 3.02 9.83 ± 2.38 <0.01 22.77 ± 3.13 13.44 ± 2.82 <0.01
HOMA-IR 3.99 ± 2.00 2.97 ± 1.79 <0.01 3.48 ± 1.28 3.67 ± 1.59 0.11
HOMA-β 42.72 ± 25.63 45.83 ± 21.21 0.63 40.55 ± 19.72 39.88 ± 17.22 0.37
IGI 4.39 ± 1.41 4.92 ± 2.37 0.33 3.77 (1.25-6.08) 4.27 (1.47-6.81) 0.58
Matsuda 5.97 ± 3.96 4.98 ± 2.51 0.15 4.54 (3.15-6.01) 4.58 (3-7.63) 0.78
MBCI 5.44 ± 3.33 7.27 ± 5.04 0.045 4.64 (3.39-6.77) 4.04 (2.83-7.38) 0.56
HOMA-IS∗HOMA-β 11.67 ± 5.32 14.44 ± 6.82 0.01 11.85 ± 5.86 12.06 ± 6.69 0.71
Matsuda∗MBCI 22.43 ± 11.61 26.17 ± 13.56 0.37 21.25 ± 11.87 20.57 ± 10.01 0.09

ALT: glutamic pyruvic transaminase; AST: glutamic oxalacetic transaminase; BMI: body mass index; DBP: diastolic blood pressure; FGF-21: fibroblast growth factor 21; FINS: fasting insulin; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; HOMA-β: homeostasis model assessment of β-cell function; HOMA-IR: homeostatic model assessment of insulin resistance; LFC: liver fat content; MBCI: modified β-cell function; SAT: subcutaneous and visceral adipose tissue; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; VAT: visceral adipose tissue; WC: waist circumference; 2hFBG: 2 h plasma blood glucose. Data are expressed as the mean ± standard deviation or median (interquartile range).